The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | HdxSim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in SCD
Alexandra Power-Hays, MD, Cincinnati Children’s, Cincinnati, OH, briefly discusses the development and validation of HdxSim, a clinical decision support tool for model-informed precision dosing (MIPD) of hydroxyurea in children with sickle cell disease (SCD), which has been used to optimize pharmacokinetic (PK)-guided dosing in the ADAPT trial (NCT05662098). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
